Jakub Jonczyk

Krakow, MA 30688, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 47 publications

Overcoming Resistance in Triple-Negative Breast Cancer: A Translational Perspective on Next-Generation DNA Damage Response Inhibitors and Synthetic Lethality.

Overcoming Resistance in Triple-Negative Breast Cancer: A Translational Perspective on Next-Generation DNA Damage Response Inhibitors and Synthetic Lethality.

Journal: Molecules (Basel, Switzerland)

Published: May 14, 2026

First Sustainable One-Pot Tandem Hantzsch Multicomponent Reaction/Click Reaction Approach for Novel Multitarget-Directed Ligands in Alzheimer's Disease.

First Sustainable One-Pot Tandem Hantzsch Multicomponent Reaction/Click Reaction Approach for Novel Multitarget-Directed Ligands in Alzheimer's Disease.

Journal: ACS chemical neuroscience

Published: December 29, 2025

Integrative Profiling for BBB Permeability Using Capillary Electrochromatography, Experimental Physicochemical Parameters, and Ensemble Machine Learning.

Integrative Profiling for BBB Permeability Using Capillary Electrochromatography, Experimental Physicochemical Parameters, and Ensemble Machine Learning.

Journal: International journal of molecular sciences

Published: November 21, 2025

Machine Learning-Driven Discovery of GABA-A Ligands with Pronounced Neuroprotective Efficacy and Resistance to P-gp Efflux.

Machine Learning-Driven Discovery of GABA-A Ligands with Pronounced Neuroprotective Efficacy and Resistance to P-gp Efflux.

Journal: ChemMedChem

Published: July 17, 2025

Targeting GABAergic Hypofunction Associated with Schizophrenia: Identification of α1β2γ2GABA-A Receptor Ligands with Neuroprotective and Antipsychotic Properties.

Targeting GABAergic Hypofunction Associated with Schizophrenia: Identification of α1β2γ2GABA-A Receptor Ligands with Neuroprotective and Antipsychotic Properties.

Journal: ACS chemical neuroscience

Published: June 06, 2025

Classic Psychedelics in Pain Modulation: Mechanisms, Clinical Evidence, and Future Perspectives.

Classic Psychedelics in Pain Modulation: Mechanisms, Clinical Evidence, and Future Perspectives.

Journal: ACS chemical neuroscience

Published: June 06, 2025

In vitro repositioning therapy with olaparib, temozolomide and oxaliplatin in glioblastoma cell lines: U118, U87, U251, H4 and human fibroblasts.

In vitro repositioning therapy with olaparib, temozolomide and oxaliplatin in glioblastoma cell lines: U118, U87, U251, H4 and human fibroblasts.

Journal: Pharmacological reports : PR

Published: April 24, 2025

Serotonin 2A (5-HT2A) receptor as evolving biological target: function, structure, ligands and role in the therapy of neuropsychiatric diseases.

Serotonin 2A (5-HT2A) receptor as evolving biological target: function, structure, ligands and role in the therapy of neuropsychiatric diseases.

Journal: Neuropharmacology

Published: February 13, 2025

Preferential Synaptic Type of GABA-A Receptor Ligands Enhancing Neuronal Survival and Facilitating Functional Recovery After Ischemic Stroke.

Preferential Synaptic Type of GABA-A Receptor Ligands Enhancing Neuronal Survival and Facilitating Functional Recovery After Ischemic Stroke.

Journal: Journal of medicinal chemistry

Published: December 13, 2024

Multifunctional, Fluorene-Based Modulator of Cholinergic and GABAergic Neurotransmission as a Novel Drug Candidate for Palliative Treatment of Alzheimer's Disease.

Multifunctional, Fluorene-Based Modulator of Cholinergic and GABAergic Neurotransmission as a Novel Drug Candidate for Palliative Treatment of Alzheimer's Disease.

Journal: Angewandte Chemie (International ed. in English)

Published: October 23, 2024

Virtual Screening Approaches to Identify Promising Multitarget-Directed Ligands for the Treatment of Autism Spectrum Disorder.

Virtual Screening Approaches to Identify Promising Multitarget-Directed Ligands for the Treatment of Autism Spectrum Disorder.

Journal: Molecules (Basel, Switzerland)

Published: September 30, 2024

Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents.

Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents.

Journal: Biomolecules

Published: May 31, 2024

Showing 1-12 of 47

Last Updated: 09/26/2026